Comparative Pharmacology
Head-to-head clinical analysis: DIULO versus ENDURONYL FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIULO versus ENDURONYL FORTE.
DIULO vs ENDURONYL FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the Na+/Cl- symporter in the distal convoluted tubule of the nephron, reducing reabsorption of sodium and chloride, leading to increased diuresis and decreased extracellular fluid volume.
Enduronyl Forte is a combination of methyclothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, and deserpidine, a Rauwolfia alkaloid that depletes catecholamines from adrenergic nerve endings, resulting in reduced peripheral vascular resistance and CNS sedation.
2.5 mg orally once daily, may increase to 5 mg once daily after 4 weeks if needed.
Oral: Initial 2.5-5 mg once daily; increase as needed to maximum 20 mg once daily.
None Documented
None Documented
Terminal elimination half-life is 1.5-2 hours (mean 1.8 h) in healthy adults; prolonged to 3-6 hours in renal impairment and up to 8 hours in severe heart failure.
Terminal elimination half-life: 24-48 hours (avg. 36 h); due to long half-life, requires caution in renal impairment.
Primarily renal excretion (60-70% as unchanged drug) via glomerular filtration and tubular secretion; approximately 10-15% biliary/fecal elimination.
Renal: ~50% unchanged; Biliary/Fecal: ~50% as metabolites and unchanged drug.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic + Rauwolfia Alkaloid